XLO vs. IMRX, NBRV, SNSE, RMTI, HCWB, LEXX, NXTC, UNCY, OCUP, and CARA
Should you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Immuneering (IMRX), Nabriva Therapeutics (NBRV), Sensei Biotherapeutics (SNSE), Rockwell Medical (RMTI), HCW Biologics (HCWB), Lexaria Bioscience (LEXX), NextCure (NXTC), Unicycive Therapeutics (UNCY), Ocuphire Pharma (OCUP), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry.
Immuneering (NASDAQ:IMRX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
Immuneering currently has a consensus target price of $13.50, suggesting a potential upside of 759.87%. Given Xilio Therapeutics' higher probable upside, analysts clearly believe Immuneering is more favorable than Xilio Therapeutics.
Immuneering has higher revenue and earnings than Xilio Therapeutics. Immuneering is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Immuneering has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500.
Xilio Therapeutics' return on equity of -55.79% beat Immuneering's return on equity.
In the previous week, Xilio Therapeutics had 2 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Xilio Therapeutics and 4 mentions for Immuneering. Immuneering's average media sentiment score of 0.19 beat Xilio Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media.
Immuneering received 13 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 61.54% of users gave Immuneering an outperform vote.
67.7% of Immuneering shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 25.0% of Immuneering shares are owned by insiders. Comparatively, 4.6% of Xilio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Immuneering beats Xilio Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Xilio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xilio Therapeutics Competitors List
Related Companies and Tools
